Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18616089 | Methods of treating or reducing symptoms of brain cancer such as glioma and glioblastoma via combination therapy with allosteric modulators and phenethylamines. | March 2024 | June 2025 | Abandon | 15 | 2 | 1 | No | No |
| 18218312 | Simplified Method for Making Shelf Stable Highly Water Soluble Anhydrous Compositions Of Cyclodextrin Complexes of Macrocyclic Lactones | July 2023 | August 2024 | Abandon | 14 | 2 | 1 | Yes | No |
| 18126221 | LIQUID PHARMACEUTICAL FORMULATIONS OF TOPIRAMATE | March 2023 | June 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18114502 | LIQUID PHARMACEUTICAL COMPOSITIONS OF BACLOFEN FOR ORAL ADMINISTRATION | February 2023 | July 2024 | Abandon | 16 | 3 | 0 | Yes | No |
| 18154470 | PHARMACEUTICALLY STABLE PILOCARPINE FORMULATIONS WITH SUBSTANTIALLY REDUCED BUFFER CONTENT AND RELATED METHODS | January 2023 | November 2024 | Abandon | 22 | 4 | 0 | No | No |
| 17985338 | Anhydrous Compositions Of Polysorbates For Shelf Stable Drug Combinations | November 2022 | March 2024 | Abandon | 16 | 3 | 0 | Yes | No |
| 17922758 | An Antiperspirant Composition | November 2022 | June 2024 | Abandon | 19 | 2 | 1 | No | No |
| 17721840 | MEDICATED DRINK | April 2022 | January 2025 | Abandon | 33 | 4 | 1 | Yes | No |
| 17686928 | POLYMER BASED HYDROGELS, AEROGELS, AND COMBINATIONS THEREOF | March 2022 | September 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17676224 | AQUEOUS LIQUID COSMETIC AND PEN-SHAPED COSMETIC PRODUCT | February 2022 | November 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17583636 | NANO- OR MICRO-EMULSION COMPOSITIONS AND METHODS OF USE THEREOF | January 2022 | July 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17576804 | Fermented Composition for Topical Application to Skin | January 2022 | December 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17626914 | CONTINUOUS METHOD FOR NANO-EMULSIFICATION BY CONCENTRATION PHASE INVERSION | January 2022 | November 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17290522 | MAMC-MEDIATED BIOMIMETIC NANOPARTICLES | January 2022 | June 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17564268 | LYOPHILIZED POWDER OF LATAMOXEF SODIUM FOR INJECTION AND LYOPHILIZATION METHOD THEREOF | December 2021 | May 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17645756 | Lip Gloss Formulation | December 2021 | January 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17560328 | CREAMY HYDRATING COSMETIC COMPOSITION IN A WATER RELEASE EMULSION | December 2021 | January 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17549970 | Method Of Manufacturing Cosmetic Compositions Comprising Sucrose Esters And Solvents | December 2021 | June 2024 | Allow | 30 | 4 | 0 | Yes | No |
| 17544228 | STABLE DISPERSIONS OF SILVER NANOPARTICLES AND METHODS OF PREPARATION THEREOF | December 2021 | June 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17534801 | TRANSDERMAL DRUG DELIVERY DEVICE/TRANSDERMAL PATCH AND OTHER APPLICATIONS OF EMULSION FORMULATION | November 2021 | June 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17612159 | METHODS AND COMPOSITIONS FOR TREATING UNDESIRED IMPLANTED TISSUE FILLER | November 2021 | September 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17525914 | INTRAVENOUS PHYSIOLOGICAL SOLUTION TO OPTIMIZE FLUID THERAPY IN PATIENTS | November 2021 | March 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17610660 | POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDS | November 2021 | April 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17608347 | DI-THIOESTER CATIONIC LIPIDS | November 2021 | June 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17605585 | FUSOGENIC PARTICLES AND RELATED METHODS FOR DELIVERING THERAPEUTIC AGENTS TO CELLS | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17481730 | COMPOSITION OF SUSPOEMULSION FORMULATION OF ANTHELMINTIC DRUGS WITH ESSENTIAL OILS FOR NASO-PULMONARY ADMINISTRATION | September 2021 | September 2024 | Abandon | 36 | 4 | 1 | Yes | No |
| 17476911 | PEPTIDE MICROPARTICLE STRUCTURE | September 2021 | August 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17467955 | SKIN CARE FORMULA, SKIN CARE PRODUCTS, AND METHODS OF MAKING THE SAME | September 2021 | December 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17443498 | TRANSMEMBRANE PORES FORMED BY AROMATIC OLIGOAMIDE FOLDAMERS AND USES OF SAME | July 2021 | October 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17383817 | FUNCTIONALIZED SET OF CARBON ATOMS IN THE SP2 HYBRIDIZATION STATE, A METHOD FOR PREPARING IT AND ITS USES, IN PARTICULAR FOR RENDERING A SURFACE ANTIBACTERIAL | July 2021 | March 2025 | Abandon | 44 | 3 | 1 | No | No |
| 17418337 | AGENT FOR INHIBITING REDUCTION IN DECOMPOSITION OF DENATURED ELASTIN, AGENT FOR MAINTAINING NORMAL ELASTIN FIBERS, AGENT FOR INHIBITING FORMATION OF ELASTIN-ELAFINE COMPOSITE, AND SCREENING METHOD FOR SUBSTANCE HAVING ELASTIN-ELAFINE COMPOSITE FORMATION INHIBITORY EFFECT | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17413091 | COMPOSITION COMPRISING A POLYSACCHARIDE, A POLYOL AND A SPECIFIC ESTER | June 2021 | February 2025 | Abandon | 44 | 3 | 1 | No | No |
| 17315089 | POUCHES | May 2021 | September 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17291247 | COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND MICROTUBULE ASSEMBLY INHIBITOR HERBICIDES | May 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17246018 | Compositions and Methods for Treating Dopamine Disorders | April 2021 | December 2024 | Abandon | 44 | 4 | 1 | No | No |
| 17238809 | SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS | April 2021 | November 2024 | Allow | 43 | 2 | 1 | Yes | Yes |
| 17287344 | Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations | April 2021 | November 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17235314 | TRANSDERMAL AND/OR TOPICAL, PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | April 2021 | May 2025 | Abandon | 48 | 3 | 1 | No | No |
| 17233493 | METHOD OF STABLE FORMULATION OF MICROBIAL AND MICROBE DERIVED PRODUCTS AND USE OF SAME | April 2021 | June 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17223671 | STABILIZED LIQUID ENZYME SUPPLEMENT AND USES THEREOF | April 2021 | May 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17282809 | CORE-SHELL STRUCTURE FOR ESTABLISHING NORMAL AND CANCER ORGANOID MICROENVIRONMENT AND FABRICATION METHOD THEREFOR | April 2021 | November 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17220456 | ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENT | April 2021 | March 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17219295 | METHODS AND COMPOSITIONS FOR DRUG DELIVERY | March 2021 | May 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17214868 | SUPPOSITORIES COMPRISING CANNABINOIDS | March 2021 | December 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17276478 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY SYSTEMS FOR PREVENTION AND TREATMENT OF CANDIDIASIS | March 2021 | January 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17196567 | Novel Compounds and Pharmaceutical Preparations | March 2021 | July 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17274223 | FUNGICIDAL NITROANILINO SUBSTITUTED PYRAZOLES | March 2021 | April 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17250714 | CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE | February 2021 | January 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17183157 | Immobilization of Plant Growth Promoting Microorganisms in Hydrophobic Carriers | February 2021 | May 2025 | Abandon | 51 | 3 | 1 | No | Yes |
| 17268769 | METHOD FOR PREPARING MICROCAPSULE | February 2021 | March 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17256522 | FERMENTED BIRCH SAP AND METHOD FOR PRODUCING IT | December 2020 | August 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17053429 | INJECTION FORMULATION COMPOSITION FOR USE AS FILLER OR DRUG CARRIER THROUGH CLICK CHEMISTRY REACTION | November 2020 | November 2024 | Abandon | 49 | 4 | 1 | Yes | No |
| 17053434 | MICROBACTERIUM ISOLATES AND USES THEREOF | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17047222 | HAIRCARE COMPOSITION COMPRISING MODIFIED VEGETABLE WAXES | October 2020 | December 2024 | Allow | 50 | 3 | 1 | Yes | No |
| 17046726 | METHOD OF CONTROLLING SOIL-BORNE DISEASES OF PLANTS | October 2020 | April 2025 | Abandon | 54 | 3 | 1 | No | No |
| 17045204 | WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE (HPPD) INHIBITORS | October 2020 | February 2024 | Abandon | 41 | 4 | 1 | No | No |
| 17045188 | WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ACETYL CoA CARBOXYLASE (ACCase) INHIBITORS | October 2020 | February 2024 | Abandon | 40 | 4 | 1 | No | No |
| 17045178 | EMULSIFIABLE CONCENTRATE FORMULATIONS OF SDHI FUNGICIDES | October 2020 | August 2024 | Abandon | 47 | 3 | 0 | No | No |
| 16978215 | A COMPOSITION SUITABLE FOR HAIR CARE | September 2020 | March 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16975747 | METHOD OF REDUCING CROP DAMAGE | August 2020 | April 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16986745 | PLANT HEALTH WITH IN SITU FORMED WATER ABSORBING HYDROGELS | August 2020 | March 2025 | Abandon | 55 | 2 | 1 | No | No |
| 16945279 | CADAVER PRESERVATION SYSTEMS AND METHODS | July 2020 | March 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 16966704 | FIVE-MEMBERED RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF | July 2020 | April 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16966686 | PYRIDINE RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF | July 2020 | April 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16966452 | GLASS FORMULATIONS AND USES THEREOF | July 2020 | June 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16916594 | COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL CONTAINING A COMBINATION OF SILICONE RESINS | June 2020 | February 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 16500688 | PROCESS FOR DYEING HAIR COMPRISING AT LEAST ONE PIGMENT, AT LEAST ONE ACRYLATE-FUNCTIONALIZED POLYMER AND AT LEAST ONE FUNCTIONALIZED SILICONE CHOSEN FROM SILICONES FUNCTIONALIZED WITH AT LEAST ONE MERCAPTO OR THIOL GROUP | October 2019 | May 2024 | Allow | 55 | 5 | 1 | Yes | No |
| 16468423 | PUFA SALT FORMULATIONS (II) | June 2019 | March 2024 | Abandon | 57 | 5 | 1 | No | No |
| 16091219 | PERSONAL CARE COMPOSITIONS AND METHODS FOR USING SUCH COMPOSITIONS | October 2018 | September 2024 | Allow | 60 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MITCHELL, EDWIN COLEMAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MITCHELL, EDWIN COLEMAN works in Art Unit 1619 and has examined 68 patent applications in our dataset. With an allowance rate of 32.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner MITCHELL, EDWIN COLEMAN's allowance rate of 32.4% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MITCHELL, EDWIN COLEMAN receive 2.24 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MITCHELL, EDWIN COLEMAN is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +78.6% benefit to allowance rate for applications examined by MITCHELL, EDWIN COLEMAN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.9% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 13.0% of cases where such amendments are filed. This entry rate is in the 7% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.4% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.